Cipla Q2 PAT may dip 27.3% at Rs 363.3 cr: ICICIdirect

ICICIdirect.com has come out with its second quarter (July-September) earnings estimates for the pharmaceutical sector. The brokerage house expects Cipla to report a 23.5 percent degrowth quarter-on-quarter (down 27.3 percent Y-o-Y) in net profit at Rs 363.3 crore.

Revenues of Cipla are expected to decrease by 0.6 percent Q-o-Q (up 11.7 percent Y-o-Y) to Rs 2448.9 crore, according to ICICIdirect.com. Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 16.6 percent Q-o-Q (down 16.8 percent Y-o-Y) to Rs 563.3 crore. ICICIdirect.com's Report on Cipla: Standalone revenues of Cipla are expected to increase 12 percent on a higher base. Both domestic and export formulation are expected to grow 12 percent Y-o-Y. EBITDA margins are expected to decline 790 bps Y-o-Y on a higher base as it supplied generic Lexapro to Teva in Q2FY13. Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.